Cargando…
Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies
OBJECTIVE: To compare “hybrid immunity” (prior COVID‐19 infection plus vaccination) and post‐vaccination immunity to SARS CoV‐2 in MS patients on different disease‐modifying therapies (DMTs) and to assess the impact of vaccine product and race/ethnicity on post‐vaccination immune responses. METHODS:...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538694/ https://www.ncbi.nlm.nih.gov/pubmed/36165097 http://dx.doi.org/10.1002/acn3.51664 |
_version_ | 1784803382265905152 |
---|---|
author | Kister, Ilya Curtin, Ryan Pei, Jinglan Perdomo, Katherine Bacon, Tamar E. Voloshyna, Iryna Kim, Joseph Tardio, Ethan Velmurugu, Yogambigai Nyovanie, Samantha Valeria Calderon, Andrea Dibba, Fatoumatta Stanzin, Igda Samanovic, Marie I. Raut, Pranil Raposo, Catarina Priest, Jessica Cabatingan, Mark Winger, Ryan C. Mulligan, Mark J. Patskovsky, Yury Silverman, Gregg J. Krogsgaard, Michelle |
author_facet | Kister, Ilya Curtin, Ryan Pei, Jinglan Perdomo, Katherine Bacon, Tamar E. Voloshyna, Iryna Kim, Joseph Tardio, Ethan Velmurugu, Yogambigai Nyovanie, Samantha Valeria Calderon, Andrea Dibba, Fatoumatta Stanzin, Igda Samanovic, Marie I. Raut, Pranil Raposo, Catarina Priest, Jessica Cabatingan, Mark Winger, Ryan C. Mulligan, Mark J. Patskovsky, Yury Silverman, Gregg J. Krogsgaard, Michelle |
author_sort | Kister, Ilya |
collection | PubMed |
description | OBJECTIVE: To compare “hybrid immunity” (prior COVID‐19 infection plus vaccination) and post‐vaccination immunity to SARS CoV‐2 in MS patients on different disease‐modifying therapies (DMTs) and to assess the impact of vaccine product and race/ethnicity on post‐vaccination immune responses. METHODS: Consecutive MS patients from NYU MS Care Center (New York, NY), aged 18–60, who completed primary COVID‐19 vaccination series ≥6 weeks previously were evaluated for SARS CoV‐2‐specific antibody responses with electro‐chemiluminescence and multiepitope bead‐based immunoassays and, in a subset, live virus immunofluorescence‐based microneutralization assay. SARS CoV‐2‐specific cellular responses were assessed with cellular stimulation TruCulture IFNγ and IL‐2 assay and, in a subset, with IFNγ and IL‐2 ELISpot assays. Multivariate analyses examined associations between immunologic responses and prior COVID‐19 infection while controlling for age, sex, DMT at vaccination, time‐to‐vaccine, and vaccine product. RESULTS: Between 6/01/2021 and 11/11/2021, 370 MS patients were recruited (mean age 40.6 years; 76% female; 53% non‐White; 22% with prior infection; common DMT classes: ocrelizumab 40%; natalizumab 15%, sphingosine‐1‐phosphate receptor modulators 13%; and no DMT 8%). Vaccine‐to‐collection time was 18.7 (±7.7) weeks and 95% of patients received mRNA vaccines. In multivariate analyses, patients with laboratory‐confirmed prior COVID‐19 infection had significantly increased antibody and cellular post‐vaccination responses compared to those without prior infection. Vaccine product and DMT class were independent predictors of antibody and cellular responses, while race/ethnicity was not. INTERPRETATION: Prior COVID‐19 infection is associated with enhanced antibody and cellular post‐vaccine responses independent of DMT class and vaccine type. There were no differences in immune responses across race/ethnic groups. |
format | Online Article Text |
id | pubmed-9538694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95386942022-10-11 Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies Kister, Ilya Curtin, Ryan Pei, Jinglan Perdomo, Katherine Bacon, Tamar E. Voloshyna, Iryna Kim, Joseph Tardio, Ethan Velmurugu, Yogambigai Nyovanie, Samantha Valeria Calderon, Andrea Dibba, Fatoumatta Stanzin, Igda Samanovic, Marie I. Raut, Pranil Raposo, Catarina Priest, Jessica Cabatingan, Mark Winger, Ryan C. Mulligan, Mark J. Patskovsky, Yury Silverman, Gregg J. Krogsgaard, Michelle Ann Clin Transl Neurol Research Articles OBJECTIVE: To compare “hybrid immunity” (prior COVID‐19 infection plus vaccination) and post‐vaccination immunity to SARS CoV‐2 in MS patients on different disease‐modifying therapies (DMTs) and to assess the impact of vaccine product and race/ethnicity on post‐vaccination immune responses. METHODS: Consecutive MS patients from NYU MS Care Center (New York, NY), aged 18–60, who completed primary COVID‐19 vaccination series ≥6 weeks previously were evaluated for SARS CoV‐2‐specific antibody responses with electro‐chemiluminescence and multiepitope bead‐based immunoassays and, in a subset, live virus immunofluorescence‐based microneutralization assay. SARS CoV‐2‐specific cellular responses were assessed with cellular stimulation TruCulture IFNγ and IL‐2 assay and, in a subset, with IFNγ and IL‐2 ELISpot assays. Multivariate analyses examined associations between immunologic responses and prior COVID‐19 infection while controlling for age, sex, DMT at vaccination, time‐to‐vaccine, and vaccine product. RESULTS: Between 6/01/2021 and 11/11/2021, 370 MS patients were recruited (mean age 40.6 years; 76% female; 53% non‐White; 22% with prior infection; common DMT classes: ocrelizumab 40%; natalizumab 15%, sphingosine‐1‐phosphate receptor modulators 13%; and no DMT 8%). Vaccine‐to‐collection time was 18.7 (±7.7) weeks and 95% of patients received mRNA vaccines. In multivariate analyses, patients with laboratory‐confirmed prior COVID‐19 infection had significantly increased antibody and cellular post‐vaccination responses compared to those without prior infection. Vaccine product and DMT class were independent predictors of antibody and cellular responses, while race/ethnicity was not. INTERPRETATION: Prior COVID‐19 infection is associated with enhanced antibody and cellular post‐vaccine responses independent of DMT class and vaccine type. There were no differences in immune responses across race/ethnic groups. John Wiley and Sons Inc. 2022-09-27 /pmc/articles/PMC9538694/ /pubmed/36165097 http://dx.doi.org/10.1002/acn3.51664 Text en © 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Kister, Ilya Curtin, Ryan Pei, Jinglan Perdomo, Katherine Bacon, Tamar E. Voloshyna, Iryna Kim, Joseph Tardio, Ethan Velmurugu, Yogambigai Nyovanie, Samantha Valeria Calderon, Andrea Dibba, Fatoumatta Stanzin, Igda Samanovic, Marie I. Raut, Pranil Raposo, Catarina Priest, Jessica Cabatingan, Mark Winger, Ryan C. Mulligan, Mark J. Patskovsky, Yury Silverman, Gregg J. Krogsgaard, Michelle Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies |
title | Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies |
title_full | Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies |
title_fullStr | Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies |
title_full_unstemmed | Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies |
title_short | Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies |
title_sort | hybrid and vaccine‐induced immunity against sar‐cov‐2 in ms patients on different disease‐modifying therapies |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538694/ https://www.ncbi.nlm.nih.gov/pubmed/36165097 http://dx.doi.org/10.1002/acn3.51664 |
work_keys_str_mv | AT kisterilya hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT curtinryan hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT peijinglan hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT perdomokatherine hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT bacontamare hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT voloshynairyna hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT kimjoseph hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT tardioethan hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT velmuruguyogambigai hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT nyovaniesamantha hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT valeriacalderonandrea hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT dibbafatoumatta hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT stanzinigda hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT samanovicmariei hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT rautpranil hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT raposocatarina hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT priestjessica hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT cabatinganmark hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT wingerryanc hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT mulliganmarkj hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT patskovskyyury hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT silvermangreggj hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies AT krogsgaardmichelle hybridandvaccineinducedimmunityagainstsarcov2inmspatientsondifferentdiseasemodifyingtherapies |